12.07.2020 |
Scientific publications

VMX-C001 is a Bypassing Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile

Reversal of anticoagulation is important for safe usage of oral factor (F)Xa-inhibiting direct oral anticoagulants (FXa-DOACs).

Related items

24.02.2026

News, Scientific publications

VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors
Key Highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for…
Read more

24.06.2023

Scientific publications

Coagulation assays for assessing direct FXa inhibitor oral anticoagulant reversal effect
Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.
Read more